Biogen Swings to Q3 2026 Net Loss of $20.6 Million

Biogen reported third-quarter 2026 revenue of $2.8 billion, up 11% year over year, and non-GAAP diluted EPS of $2.62. GAAP results included a net loss of $20.6 million, primarily reflecting transaction-related charges. The company raised the lower end of its full-year non-GAAP diluted EPS guidance…